On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

Abbott (NYSE:ABT) today announced a significant milestone abroad with the opening of a new manufacturing facility in Ireland.

A major development towards the goal of patient and provider choice, the cloud-to-cloud integration will provide an automatic ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Abbott Laboratories (ABT) stock has had negative returns for the last 3 years. But don’t get fooled by that when analyzing the stock’s performance. For a dividend aristocrat, one needs to look ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

The company’s key products include medical devices like FreeStyle Libre for glucose monitoring and MitraClip for heart valve repair, point-of-care testing systems and infectious disease testing ...

Abbott's FreeStyle Libre 2 and 3 continuous glucose monitors no longer need to be removed for imaging tests. CGM readings during an MRI may be affected for up to an hour after the procedure. While ...